The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
